SCHEMBL21721879

SCHEMBL21721879

CC(C)c1c(-c2ccc(C#N)cc2)[nH]c2ncnn2c1=O

nearest known ligand 0.47

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
KDM5B Q9UGL1 2/20 0.47
EGLN2 Q96KS0 18/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31676980 0.86 KDM5B (0.51) KDM5BEGLN2
SCHEMBL21681725 0.86 KDM5B (0.51) KDM5BEGLN2
SCHEMBL31676981 0.85 KDM5B (0.50) KDM5BEGLN2
SCHEMBL21721786 0.85 KDM5B (0.50) KDM5BEGLN2
SCHEMBL21721691 0.85 KDM5B (0.50) KDM5B
SCHEMBL20074328 0.84 KDM5B (0.44) KDM5BEGLN2
SCHEMBL20074113 0.84 KDM5B (0.44) KDM5B
SCHEMBL20074303 0.84 CCNB2 (0.47) KDM5BEGLN2
SCHEMBL20074277 0.84 KDM5B (0.42) KDM5BEGLN2
SCHEMBL20074331 0.83 KDM5B (0.43) KDM5B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3525785-B1 KDM5 INHIBITORS MERCK SHARP & DOHME LLC (US) 2025-08-27 EP claimed
EP-3525785-B1 KDM5 INHIBITORS MERCK SHARP & DOHME LLC (US) 2025-08-27 EP disclosed
US-10975084-B2 KDM5 inhibitors MERCK SHARP & DOHME CORP. (US) 2021-04-13 US disclosed
US-20200048258-A1 KDM5 INHIBITORS MERCK SHARP & DOHME CORP. (US) 2020-02-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200048258-A1 KDM5 INHIBITORS KDM5A, KDM5B, KDM5C KDM5B 2/4885EGLN2 600/4885
US-10975084-B2 KDM5 inhibitors KDM5A, KDM5B, KDM5C KDM5B 2/4885EGLN2 600/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.